This new one-step chemiluminescent immunoassay of free thyroxin (FT4) involving a thyroxin-immunoglobulin conjugate labeled with acndinium ester (Magic Lite System; Ciba Coming Diagnostics Corp., Medfield, MA) is rapid (one 1-h incubation), requires two calibrators per run, and takes 10 s per sample for the quantification step. Analytical performances were excellent: within-and between-run CVs of <10% in the working range, no significant effect of hemolysis, bilirubin, or lipemia, and no signficant interaction between the conjugate and the thyroxin-binding proteins. 
assay, 25 pL of serum is incubated with 100 iL of "Lite" reagent (AE-BgG-T4) and 500 pL of solid phase (anti-T4 antibody) for 1 h at room temperature. Separation of bound from unbound AE-BgG-T4 is done by magnetic separation and decantation of the supernate. Test tubes containing bound AE-BgG-T4 are measured in the Magic Lite Analyzer, which automatically injects the two reagents necessary to initiate the chemiluminescent reaction. The light emission is expressed as photon counts accumulated during 2 s (relative light unit, RLU). Two VP4 calibrators are required in each assay, one low calibrator (-6 pmolIL) and one high calibrator (-40 pmoIIL), their RLU values being used to recalibrate a manufacturer-generated "Master Curve" stored in the analyzer's memory for each lot of reagents. The recalibration takes place via algorithms in the analyzer software, which transforms the spline of the Master Curve. All assays of calibrators, controls, and unknown samples were done in duplicate.
Chromatography-based radioimmunoassay for FT4. We compared results obtained with the Magic Lite VP4 assay with those of the test we use routinely, the Sclavo VP4 radioimmunoassay (Sclavo, Siena, Italy), in which the free hormone is chromatographically separated from the proteins before the competitive procedure (3).
Other assays. We measured concentrations of thyrotropin (TSH) by a chemiluminometric immunoassay (TSH Magic Lite, Ciba Corning) and concentrations of free triiodothyronine (VP3) by a chromatographic method (Sclavo). Normal reference intervals for TSH and VP3 were 0.4 to 4.8 milli-int. unitsfL and 4 to 7 pmol/L, respectively. We used "RIA-gnost" TBG kits (Hoechst-Behring, Frankfl.irt, F.R.G.) to measure thyroxin binding globulin (TBG). Prealbunuin (PA) and albumin were assayed immunonephelometrically with a method from Hoechst-Behring. Normal reference intervals for TBG, PA, and albumin were 15 to 25 mgIL, 0.3 to 0.5 g/L, and 37 to 50 g/L, respectively.
Clinical Evaluation
We measured the VP4 in 503 subjects. In each case, the thyroid status was established on the basis of clinical evaluation, measurements of VP3 and VP4 (by the Sclavo methods), basal TSH, and, if necessary, the TSH response 30 mm after intravenous administration of thyroliberin (TRH).
Euthyroid reference population.
Of the 140 euthyroid subjects, 85 had no evidence of thyroid disease and 55 had a simple goiter.
Hyperthyroid population. This consisted of 81 patients with increased concentrations of VP3 and VP4, and an absent response of TSH to TRH. Twenty-one had Graves' disease, 38 a toxic multinodular goiter, and 18 a solitary toxic nodule. Four cases of hyperthyroidism were induced by amiodarone.
Hypothyroid population. These were 46 patients with low VP3 and VP4 concentrations, and high TSH response to TRH (>20 milli-int. units/L).
"Particular" euthyroid populations. We also examined the VP4 Magic Lite performance in situations where therapies, 
Results

Analytical Variables
Precision. For evaluation of within-and between-run precision we used five pooled specimens of human serum. Intra-assay CVs (n = 11) were 11%, 9.5%, 4%, 3.5%, and 2.5% for VP4 values of 6, 10.5, 16.5, 19.5, and 43 pmoIJL respectively. Interassay CVs (n = 10) were respectively 13%, 11.5%, 7%, 8.5%, and 5%.
Detection limit. By extrapolating the interassay precision proffle iC = fTC) (absolute error vs concentration, with C = 2 SD), we derived the limit of detection as 0.7 pmol/L. Intra-assay drift. We observed no significant intra-assay drift when the same sample was positioned at the beginning and the end of 10 consecutive runs containing up to 100 tubes each (Student's paired t-test: t = 0.55, n = 10, not significant).
Effect of sample dilution. One criterion for the validity of a free hormone analysis is the lack of effect of sample dilution on the measured free hormone concentration. We assayed six different patients' samples undiluted and after being diluted two-, four-, and 10-fold with assay buffer. Three of the samples were in the euthyroid, two in the hypothyroid, and one in the hyperthyroid range. The hypothyroid and euthyroid samples could be diluted up to 10-fold without significant impact on the dilution-corrected measured VP4 (Figure 1 ). But a significant decrease in VP4 was observed in DILUTION FACTOR Fig. 1 . Effectof sample dilution on the measured Fr4concentrationin sera of three euthyroid (#{149}), onehyperthyroid(*), and two hypothyroid (#{149}) patients the case of the hyperthyroid sample. This last observation is without any practical consequence, because the sample would not be diluted before an assay.
Matrix effect. No change in VP4 concentration was observed between hemolyzed (samples supplemented with 5 g of hemoglobin per liter) and unhemolyzed serum (Student's paired t-test: t = 1.7, n = 8, not significant).
Bilirubin in concentrations up to 300 mg/L had an insignificant effect on the assay.
Nine sera were supplemented with 7.5, 15, and 30 g of triglyceride per liter (the normal range for triglyceride is -0.5-2 g/L). Significant differences in VP4 (P <0.05) between supplemented and unsupplemented samples were observed for one serum with a triglyceride concentration of 15 g/L, and for three sera with a triglyceride concentration of 30 g/L. All of these samples had high CVs-30%, 35%, 10%, and 17%-indicating a precision problem may be due to mechanical interferences from pipetting grossly lipemic samples. We concluded that the presence of triglyceride in high concentrations does not interfere with the chemistry of the assay.
Effect of albumin and TBG. We investigated the possibility of interference in the assay system generated by interaction between the tracer (AE-BgG-T4) and endogenous binding proteins. We added 0, 50, 100, and 200 mg of purified TBG (Sigma Chemical Co., St Louis, MO) per liter to the zero standard. The count rate was unaffected for TBG concentrations up to 100 mg/L (Figure 2 ). This result indicates that the AE-BgG-T4PPBG interaction is not significant for concentrations covering the normal (15-25 mg/L) and pregnancy (40-70 mg/L) ranges for TBG. A slight (10%) but significant (P <0.01) decrease in the bound radioactivity was observed only for a concentration not encountered in clinical practice, 200 mg/L.
The effect of albumin was tested by adding 15, 30, and 45 g of purified albumin (Sigma) per liter of a pool of normal sera and assaying. The VP4 values remained unaffected, indicating that the AE-BgG-T4 does not significantly interact with albumin (Figure 3) .
Effect of oleic acid. The mean concentration of NEFA is -0.7 mmol/L in normal subjects and significantly higher (3 mmol/L) in some NT! patients (4). To simulate increased NEFA, we added to a pool of normal sera 0.125, 0.5, 1, 10, and 20 mmol of oleic acid (Sigma) per liter. The free hormone remained unaffected for oleic acid concentrations up to 1 mmol/L (Figure 4) . We then observed an increase in VP4, caused by oleic acid competition for thyroxin binding sites. This increase is not peculiar to the Magic Lite assay; it can be observed with any VP4 assay. Care should be THBA interference. We assayed sera of two euthyroid subjects containing thyroid hormone autoantibodies, which were detected by the method described by Allan et al. (5) . Falsely high VP4 values (40 and 25 pmol/L) were observed by the one-step Magic Lite method. This was a result of THBA cross reaction with the tracer (AE-BgG-T4). Such interference cannot occur in the two-step Sclavo procedure in which the free hormone is physically separated from the binding components in serum before the competitive reaction. The VP4 values observed with this last method (15 and 14 pmoIJL) correlated well with the thyroid status of the two subjects.
Clinical Evaluation
Reference, hyperthyroid, and hypothyroid populations. The Magic Lite performance in these three groups was estimated by plotting on the same graph the three VP4 repartitions in cumulative frequency form. Such a representation yielded information about the diagnostic value of the free-thyroxin assay (Figure 5, top) . First, we have defined the normal reference interval as that including 95% of the euthyroid subjects. Its limits, 12 and 21.5 pmol/L, were the abscissa of the points 0.975 and 0.025 measured from the curve of the reference euthyroid repartition.
Second, we have deduced the clinical sensitivity of the assay for the diagnosis of hyperthyroidism or hypothyroidism under conditions in which the above-normal interval limits would be used in routine practice. The sensitivity was found to be 0.91 for the diagnosis of hypothyroidism (ordinate value of the low-normal limit, 12 pmol/L, measured from the hypothyroid repartition curve). The sensitivity was 0.98 for the diagnosis of hyperthyroidism (1 minus the ordinate value of the high-normal limit, 21.5 pmol/L, measured from the hyperthyroid repartition curve).
Last, the repartitions of euthyroid, hyperthyroid, and hypothyroid plotted on the same graph displayed the euthyroid/hyperthyroid and euthyroid/hypothyroid overlaps. For comparison, 95% of the euthyroid subjects ranged between 7.5 and 15 pmolIL by Sclavo (FigureS, bottom) ; the sensitivities were 0.91 and 0.95 for the diagnosis of hypothyroidism and hyperthyroidism, respectively. 'Particular" populations.
VP4
concentrations were measured in '1particular' populations by both Magic Lite and Sclavo VP4 assays ( Figure 6 ).
As compared with results for the euthyroid reference population, results by the two methods were qualitatively similar for all groups except intensive care. VP4 concentrations in elderly subjects and women taking oral contraceptive therapies were not significantly different from euthyreid values by either test. Results were significantly increased or decreased (P <0.001) in chronic renal failures, pregnant women, and patients treated by heparin, an#{252}odar-one, or levothyroxin. For the group of subjects in the intensive-care unit we observed a significant increase in VP4 by Magic Lite (Student's t-test: t = 4.2, df = 163, P <0.001) but not by the Sciavo test (t = 1.22, df = 163, not significant).
We have also compared the individual VP4 results in each "particular" group. Data were normalized by dividing each observed value by the mean of the respective reference interval (11 pmol/L and 16.5 pmol/L for the Sclavo and the Magic Lite methods, respectively). Individual VP4 were compared by use of Student's paired t-tests. The two VP4 assays gave identical results for elderly subjects and patients being treated with amiodarone or levothyroxin (Table  1 ). Significant differences (P <0.001) had been pointed out in some populations: The decline in VP4 concentrations measured by Magic Lite was greater than by the Sclavo test in cases of chronic renal failure and in pregnant women, and the increase in VP4 in subjects being treated with heparmn was less by Magic Lite than by Sclavo. These differences may be imputed to exogenous or endogenous components, NEFA for example, which may interfere in the analytical procedure to different extents for each method.
DIscussion
We found the chemiluminescent immunoassay of VP4 easy to use and reliable. In the Magic Lite assay, there is no need for a secondary reaction, such as an enzymatic one, to initiate the chemiluminescent signal. The long counting time of radioimmunoassay is not required because of the high specific activity of the chemiluminescent-labeled analyte. Each labeled molecule potentially generates one "event" (one photon emitted). In practice, only about 10% of these emit light. However, this is much greater than with I labeling, where there is one event per second for each 7.5 106molecules of label. With the Magic Lite system, there is no need for full standard curves; only a simple two-point calibration is necessary. This calibration system simplifies every assay and minimizes reagent use and operator hands- on time. Small runs to generate results for just a few patients are more economical. Our analytical evaluation indicated excellent performance of the luminescent immunoassay system for VP4: within-and between-run reproducibilities, no matrix effect4 insignificant interaction of the chemiluminescent-labeled analyte with the thyroxin-binding proteins, and good correlation with the Sciavo method. The Magic Lite one-step VP4 assay does not present the disadvantages of the analogbased one-step assays in which dependencies on albumin concentrations and exogenous or endogenous T4-binding competitors such as NEFA are well known (6-10). The Magic Lite procedure, like any one-step VP4 assay (11), is unreliable in the extremely rare situations of subjects with circulating T4 autoantibodies (fewer than one per 1000 persons in the general adult population, 5% of those with thyroid diseases).
Clinical evaluation showed that VI'4 by this luminescent immunoassay is a valuable tool in the assessment of dysthyroidism in the general population. Nevertheless, patients taking particular therapeutic substances or in unusual clinical conditions could be misclassified if VP4 is the only dysthyroid screening tool. 
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